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The American Society of Human Genetics (ASHG),
founded in 1948, is a society of researchers and pro-
fessionals in human genetics and represents more than
6,700 scientists, physicians, nurses, genetic counselors,
and students who are actively engaged in the genetic
discovery, teaching, and application of knowledge of
human genetics and the human genome.
The membership has a keen interest in gene therapy,
its scientific basis, and its translation into clinical practice,
and members are frequently called upon to provide
advice to families confronted with the opportunity to
participate in experimental gene therapy. If, in the future,
gene therapy becomes available as a routine treatment
option, many ASHG members will be involved in both
the application of gene therapy and the decision-making
process that families will undergo to determine whether
gene therapy is suitable for them or their loved ones.
As representatives of one of the few organizations
whose members share broad expertise and interest in
matters related to human genetics and in the application
of genetic knowledge to the well-being of people
everywhere, the ASHG Board of Directors has prepared
this statement.
The Need for More Rigorous Research
At this time, gene therapy is a highly experimental area
of research, and both researchers and the public would
agree that, to date, demonstrable progress has fallen
short of initial expectations. No cures can as yet be at-
tributed to gene therapy. Even the safety of gene therapy
procedures has now been called into question by recent
events involving a patient death. Both the lack of prog-
ress and the safety issues are related to a poorly devel-
oped scientific base when experimentation began and to
an initial lack of appreciation for the extensive experi-
mental work in gene delivery and gene expression that
would be required prior to clinical studies. Unrealistic
expectations have also resulted from overzealous pro-
nouncements by some gene therapy enthusiasts who
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have underestimated the complexity of the problem.
Since the appearance, in 1995, of a highly critical Na-
tional Institutes of Health (NIH) review of gene therapy,
the field has begun to mature, the scientific base has
grown considerably, and expectations—for the most
part—appear to be more firmly based in reality. Much
more, however, remains to be done.
The ASHG recognizes that gene therapy holds much
promise. However, this promise will only be achieved
through continued rigorous research on the most-fun-
damental mechanisms underlying gene delivery and
gene expression in animals. Clinical trials should be un-
dertaken only after solid evidence of both safety and
efficacy has been obtained in an appropriate animal
model, when these are available for the disease under
investigation. When clinical trials are undertaken, they
must be subjected to the same rigorous and critical
evaluation.
Who Looks After the Interests of the Patient?
In any gene therapy trial, the greatest responsibility for
patient safety lies with the investigators, who, more than
anyone, should know the potential risks and benefits of
the proposed trial. The investigators also have access to
all data accumulated during a trial and are able to assess
risk factors continuously throughout the trial, allowing
them to make adjustments as the trial proceeds.
The local institutional review board (IRB) has a man-
date to evaluate each protocol adequately prior to ap-
proving any clinical trial. The IRB also has a respon-
sibility to require that all relevant information generated
during the trial be made available so that the estimated
risk/benefit ratio can be continuously updated. It must
also require investigators to monitor developments in
the field and to report them to the IRB so that the trial
may be stopped or revised if a significant new devel-
opment makes the current protocol inferior in terms of
either risk or efficacy.
Issues related to potential conflict of interest must also
be continually monitored by the IRB, to ensure that
decisions regarding clinical trials are made on the basis
of sound scientific and medical judgment, with primary
regard for the patient’s well-being, and are unclouded
by motivations related to personal gain or publicity.
Indeed, many would argue that financial interest in a
commercial venture should preclude direct participation
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in a clinical trial supported by that commercial enter-
prise.
All scientists and clinicians with relevant expertise,
regardless of whether they are involved in clinical trials,
have a responsibility to speak up if a gene therapy pro-
tocol seems inadequate or dangerous on the basis of the
evidence at hand. Such individuals, many of whom are
ASHG members, have an opportunity to evaluate data
pertaining to the efficacy or safety of an experimental
protocol, through review of the scientific literature, at-
tendance at scientific meetings, or participation in re-
view panels. They are therefore in a position to serve
as watchdogs at the most fundamental level of clinical
investigation, and they have a responsibility commen-
surate with this privileged position.
In the United States, the Food and Drug Administra-
tion (FDA) is the only independent agency that has re-
sponsibility for all the proposals and that has the ex-
pertise necessary to evaluate them. The FDA’s regula-
tory role in establishing standards for gene therapy trials
is critical. Similarly, the Recombinant DNA Advisory
Committee (RAC), which has responsibility for recom-
binant DNA technology (one of the building blocks of
gene therapy), must ensure that the technology is safe
and adequate for the task of gene therapy research. Fur-
ther oversight is provided by the NIH, for those insti-
tutions that receive NIH funding.
For all of these groups, the problem is in determining
when a new procedure is ready for a clinical trial and
who should be enrolled in the trial. With regard to the
latter problem, the ASHG Board of Directors suggests
a “litmus test” for its members: if you or your family
were in this circumstance, would you enroll yourself or
your loved one in this trial? Only if the answer is “yes”
is it appropriate to seek patients for enrollment or to
support a family’s decision to enter a clinical trial.
The ASHG suggests that most patients and their fam-
ilies cannot apply the litmus test to themselves. They
usually do not know enough about the science that de-
termines the potential risks and benefits of the proce-
dure, and their emotional involvement makes it difficult
to make independent decisions. They therefore require
assistance and unbiased information when making the
decision to participate (or not to participate) in a clinical
trial—the very basis of “informed” consent. The process
of obtaining informed consent can be assisted and/or
monitored by the FDA, the local IRB, and the geneticists
or other physicians who know the families; all should
apply the litmus test when making their judgments.
However, it is fundamentally the obligation of the in-
vestigator to apply this litmus test and to proceed only
if it is clear that “yes” is the appropriate and unequiv-
ocal response.
As stewards of the field of human genetics, elected
by the membership of the Society, the ASHG Board of
Directors affirms that the development and future ap-
plication of gene therapy require the same commitment
to scientific integrity and social responsibility that has
served our field well for the past 50 years. The consid-
erable promise of gene therapy must not be lost in the
wake of premature claims and tragic consequences in
some clinical trials. The appropriate course is to proceed
with a greater commitment to rigorous critical evalu-
ation and a heightened sense of responsibility to the
patients who entrust their life and health to us.
